---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-24-000041"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:22:23.602493+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC

## Summary
- Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.
- Cash $495.7M; expected to fund operations into H2 2026.
- Positive 12-week data from 320 mg cohort of INTEGRIS-PSC: reduced ELF and PRO-C3, improved bile flow.
- BEACON-IPF Phase 2b enrolling ~270 patients; 24-week PSC data expected mid-2024.
- PLN-101095 Phase 1 solid tumors enrolling third cohort; DMD regulatory filing expected Q1 2024.

## SEC filing metadata
- accession: 0001746473-24-000041
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/0001746473-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/plrx-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-24-000041
- JSON: https://secwatch.observer/filing/0001746473-24-000041.json
- Plain text: https://secwatch.observer/filing/0001746473-24-000041.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss was $41.1 million.
  - Period: fourth quarter ended December 31, 2023
  - Net income: Net loss was $41.1 million
  - Result: reported results
  source text: Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/0001746473-24-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.